Loading...
XNASICCC
Market cap46mUSD
Jan 08, Last price  
5.17USD
1D
-4.44%
1Q
39.73%
Jan 2017
-13.11%
Name

ImmuCell Corp

Chart & Performance

D1W1MN
XNAS:ICCC chart
P/E
P/S
2.64
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
7.15%
Rev. gr., 5y
9.72%
Revenues
17m
-5.90%
3,696,2804,983,1424,801,2706,069,1874,633,6904,508,6464,386,1965,111,1435,389,9356,007,1767,596,87410,228,6899,543,96110,431,00010,986,00013,723,00015,342,00019,243,00018,568,00017,471,669
Net income
-6m
L+131.54%
143,519707,782647,137662,138-468,557-216,493-384,684-409,51089,512117,395-167,1591,213,239508,448-168,000-2,322,000-1,296,000-1,022,000-78,000-2,494,000-5,774,598
CFO
-5m
L+202.76%
1,358,036764,7771,358,036349,55753,137-109,665-808,613-37,315344,3901,098,660302,3642,900,236-323,9021,175,823-373,404233,5111,315,578954,170-1,543,871-4,674,236
Earnings
Feb 25, 2025

Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
IPO date
May 01, 1987
Employees
66
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
17,472
-5.90%
18,568
-3.51%
Cost of revenue
22,693
23,131
Unusual Expense (Income)
NOPBT
(5,221)
(4,563)
NOPBT Margin
Operating Taxes
5
8
Tax Rate
NOPAT
(5,226)
(4,571)
Net income
(5,775)
131.54%
(2,494)
3,097.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
30,670
BB yield
-64.92%
Debt
Debt current
2,073
1,071
Long-term debt
19,339
13,658
Deferred revenue
Other long-term liabilities
Net debt
20,433
8,937
Cash flow
Cash from operating activities
(4,674)
(1,544)
CAPEX
(1,893)
(3,975)
Cash from investing activities
(1,890)
(3,964)
Cash from financing activities
1,751
1,114
FCF
(8,862)
(8,983)
Balance
Cash
979
5,792
Long term investments
Excess cash
105
4,864
Stockholders' equity
(11,226)
(5,451)
Invested Capital
52,909
48,306
ROIC
ROCE
EV
Common stock shares outstanding
7,748
7,745
Price
5.09
-16.56%
6.10
-23.75%
Market cap
39,436
-16.53%
47,245
-22.22%
EV
59,869
56,182
EBITDA
(5,221)
(2,075)
EV/EBITDA
Interest
341
Interest/NOPBT